Acute sources of mitochondrial NAD+ during respiratory chain dysfunction by Chinopoulos, Christos




Acute sources of mitochondrial NAD+ during respiratory chain dysfunction
Christos Chinopoulos
Department of Medical Biochemistry, Semmelweis University, Tuzolto st. 37-47, Budapest 1094, Hungary












A B S T R A C T
It is a textbook definition that in the absence of oxygen or inhibition of the mitochondrial respiratory chain by
pharmacologic or genetic means, hyper-reduction of the matrix pyridine nucleotide pool ensues due to im-
pairment of complex I oxidizing NADH, leading to reductive stress. However, even under these conditions, the
ketoglutarate dehydrogenase complex (KGDHC) is known to provide succinyl-CoA to succinyl-CoA ligase, thus
supporting mitochondrial substrate-level phosphorylation (mSLP). Mindful that KGDHC is dependent on pro-
vision of NAD+, hereby sources of acute NADH oxidation are reviewed, namely i) mitochondrial diaphorases, ii)
reversal of mitochondrial malate dehydrogenase, iii) reversal of the mitochondrial isocitrate dehydrogenase as it
occurs under acidic conditions, iv) residual complex I activity and v) reverse operation of the malate-aspartate
shuttle. The concept of NAD+ import through the inner mitochondrial membrane as well as artificial means of
manipulating matrix NAD+/NADH are also discussed. Understanding the above mechanisms providing NAD+ to
KGDHC thus supporting mSLP may assist in dampening mitochondrial dysfunction underlying neurological
disorders encompassing impairment of the electron transport chain.
1. Introduction: NAD+
Nicotinamide adenine dinucleotide (NAD+) was discovered by
Harden and Young in 1906 as a low molecular weight substance present
in yeast extract stimulating fermentation (Harden and Young, 1906).
Since then and through more than 80,000 publications, NAD+ has been
identified as a reactant in hundreds of reactions, a redox cofactor and a
key signaling molecule regulating the cell’s response to environmental
changes (Rajman et al., 2018), (Xiao et al., 2018), (Katsyuba et al.,
2020). According to BRENDA database (Jeske et al., 2019), an elec-
tronic resource comprising extensive information on IUBMB-classified
enzymes https://www.brenda-enzymes.org/, NAD+ is a substrate or
product in 633 reactions occurring in the human body; however, this is
likely an overestimation, because by combining several databases and
applying sophisticated bioinformatic analysis the group of Mootha re-
ported that in the liver there are 352 known or predicted enzymes
producing or consuming NADP(H) or NAD(H) or using them as a redox
co-factor (Goodman et al., 2018).
A mammalian cell is estimated to contain 0.2–0.5 mM [NAD+]
(Canto et al., 2015), (Yang et al., 2007), although it cannot be over-
emphasized that exactly due to its participation in many processes its
levels vary considerably in response to diverse stimuli involving nu-
tritional challenges, exercise and circadian cycles (Canto et al., 2015),
(Goodman et al., 2018). Adding to this complexity is the distribution of
NAD+ among subcellular compartments; allowing for cell-to-cell
variations, cytosolic/nuclear NAD+ is ~100 μM, while mitochondria
contain ~250 μM (Cambronne et al., 2016). Furthermore -under
normal conditions- in the cytosol the NADH/NAD+ can be up to 1:
1000 (Veech et al., 1969). On the other hand, in mitochondria the
NADH/NAD+ ratio is 1:10 due to a more reduced matrix environment,
depending on respiratory and metabolic activity (Veech et al., 1969).
For excellent, most recent reviews regarding NAD+ compartmentation
the reader is referred to that by (Kulkarni and Brookes, 2019) and
(Katsyuba et al., 2020). Finally, it is important to consider that a frac-
tion of total [NAD+] is bound to proteins, thus it cannot contribute to
the free NAD+/NADH ratio (Ansari and Raghava, 2010).
2. NAD+ involvement in neurological diseases
Mindful that NAD+ exhibits a critical role in diverse cellular pro-
cesses (Garten et al., 2015) and in view of the plethora of findings soon
after the discovery that it is a co-substrate for sirtuins and poly-ADP-
ribose polymerases (PARPs) (Imai and Guarente, 2014), (Gibson and
Kraus, 2012), realizing its involvement in human disease was in-
evitable. This unfolds through many paths, the most well-studied being
PARP hyper-activation leading to severe depletion of cellular NAD+
stores in response to extensive DNA damage (Bai, 2015), (Belenky et al.,
2007), (Morales et al., 2014).
Involvement of NAD+ in disorders of the nervous system is no ex-
ception (Owens et al., 2013), (Imai and Guarente, 2014), (Katsyuba and
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Auwerx, 2017), (Katsyuba et al., 2020); there even more so, a mi-
tochondrial protein, SARM1, was reported to cause cell destruction
through depletion of NAD+ in neuronal injuries (Essuman et al., 2017),
(Gerdts et al., 2015), (Osterloh et al., 2012), thus pinpointing the en-
zyme as a promising therapeutic drug target (Conforti et al., 2014),
(Gerdts et al., 2016)). Apart from SARM1, mitochondria also harbor
Nudix hydrolases, a superfamily of hydrolytic 'housecleaning' enzymes
that catalyze the cleavage of nucleoside diphosphates linked to x (i.e.,
any moiety) (Bessman et al., 1996), (McLennan, 2006), (see (Shumar
et al., 2018) for an exception to this rule). A link between mitochondrial
Nudix hydrolases and neurodegeneration has been addressed in (Long
et al., 2017).
From the above it is evident that since the deficiency of NAD+ may
lead to neuropathology, elevating its concentration has been shown to
be neuroprotective in many settings, such as in neuronal death induced
by ischemic brain damage (Klaidman et al., 2003), (Sadanaga-Akiyoshi
et al., 2003), (Kabra et al., 2004), (Feng et al., 2006), (Kaundal et al.,
2006), (Zheng et al., 2012), axonal degeneration in spinal cord injury
(Xie et al., 2017), traumatic brain injury, multiple sclerosis, Alzheimer's
and Parkinson's disease (Lingor et al., 2012), (Johnson et al., 2013),
(Wang et al., 2005), (Gerdts et al., 2015). By the same token replen-
ishment of NAD+ directly or by precursors through nutritional or other
means (Wang et al., 2005), (Sasaki et al., 2006), (Araki et al., 2004)
delayed axonal degeneration (Qin et al., 2006), (Gong et al., 2013), (Liu
et al., 2013), (Turunc Bayrakdar et al., 2014), (Wang et al., 2016), or
thwarted degenerative progress of both neurons (Lehmann et al., 2017)
(Zhou et al., 2015), (Hamity et al., 2017) and astrocytes (Alano et al.,
2004). Neuroprotective effects of elevating intracellular NAD+ was also
reported in ophthalmic and auditory degeneration models (Shindler
et al., 2007), (Williams et al., 2017), (Brown et al., 2014), (Someya
et al., 2010). It is thus not surprising that big pharma expresses intense
interest in regimes boosting intracellular NAD+ levels (Yoshino et al.,
2018), (Bogan and Brenner, 2008), (Katsyuba et al., 2020).
Having established that intracellular NAD+ deficiency may lead to
neuropathology, it remains to be understood as of why is this occurring.
Although this is not the topic of the present review, it is worth men-
tioning that despite that a decline in electron transport chain (ETC)
activity associated with human diseases (Vafai and Mootha, 2012),
(Wallace, 2005) has been traditionally attributed to a diminished
capacity for ATP production through OXPHOS, the contribution of the
associated reduction in NADH/NAD+ (i.e. decrease in [NAD+]) has not
been addressed adequately (Vafai and Mootha, 2012). This decrease in
NADH/NAD+ ratio commonly referred to as “reductive stress” (Xiao
and Loscalzo, 2019) forms a rapidly developing emerging topic of in-
terest, see under section “reductive stress”; the vast body of reviews
have focused on rather chronic, more sustained NAD+-boosting stra-
tegies (Canto et al., 2015), (Klimova and Kristian, 2019), (Katsyuba
et al., 2020) and references therein. Hereby, multiple sources of NADH
oxidation in the matrix are being discussed, which could be sources of
immediate provision for NAD+.
3. Reductive stress
“Reductive stress” was a term introduced by the group of Lemasters
in 1989 while demonstrating that in rat hepatocytes undergoing che-
mical anoxia, a blockade in mitochondrial respiration and ATP pro-
duction ensued (Gores et al., 1989). The authors proposed that upon
reoxidation, the electron carriers which were over-reduced during the
hypoxia treatment led to a burst of ROS generation which they termed
“reductive stress”. Currently, a more generalized definition is applied in
which an imbalance between cellular pro-oxidant levels and reducing
capacity in favor of the latter is in place (Handy and Loscalzo, 2012),
(Loscalzo, 2016), (Sarsour et al., 2009). In the vast majority of cases,
reductive stress refers to an excess of NADH, NADPH, GSH and protein
cysteine thiols over the respective oxidized counterparts (Xiao and
Loscalzo, 2019), (Perez-Torres et al., 2017). This reductive stress by
means of diminishing cell growth responses altering the balance of
protein disulfide bonds in proteins, reducing mitochondrial functions
and decreasing cellular metabolism (Perez-Torres et al., 2017), (Maity
et al., 2016), (Xiao and Loscalzo, 2019) contribute to the development
of many diverse diseases (Handy and Loscalzo, 2017), (Perez-Torres
et al., 2017), (Xiao and Loscalzo, 2019), including those encompassing
neurodegeneration (Lloret et al., 2016),(Wu et al., 2016). Mechanisms
integrating reductive stress and diverse conditions are summarized in
Fig. 1 (obtained from (Perez-Torres et al., 2017) distributed under the
Creative Commons Attribution License v 4.0). Finally, the notion that
addition of pyruvate to Rho0 cells which are respiration-deficient due
to deleterious mtDNA mutations (or complete lack thereof) (King and
Fig. 1. Participation of reducing equivalents, antioxidant enzymes and pathologies in reductive stress (obtained from (Perez-Torres et al., 2017) distributed under the
Creative Commons Attribution License v 4.0). Abbreviations: ER = endoplasmic reticulum, G6PD = glucose 6 phosphate dehydrogenase, GCL: γ-glutamyl-cysteine
ligase, GR = glutathione reductase, GSH = glutathione, GSSG = glutathione disulfide, GSHS = glutathione synthetase, GPx = Glutathione peroxidase, Grd =
glutaredoxin, Hsp = heat shock protein, IL6 = interleukin 6, NrF2 = erythroid related factor 2, OS = oxidative stress, PPP = pentose phosphate pathway, ROS =
reactive oxidative species, Se = selenium, TNFα = tumor necrosis factor alpha, Trx = thioredoxin.
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Attardi, 1989) enabling their proliferation by means of alleviating a
reductive stress (Birsoy et al., 2015), (Sullivan et al., 2015) attests to
the overall burden incompetent mitochondria pose to the harboring
cell. Mindful of the above, acute NADH oxidation mechanisms may help
to alleviate against reductive stress, reviewed below.
4. Acute provision of NAD+ through mitochondrial diaphorases
Diaphorases are flavoenzymes catalyzing the oxidation of NAD(P)H
by endogenous or artificial electron acceptors. Purification of a dia-
phorase was first reported by Bruno Ferenc Straub in 1939 (Straub,
1939). After the hiatus in research due to the II World War, research on
diaphorases was spearheaded by Lars Ernster; he coined the term DT-
diaphorases because of their reactivity with both DPNH (NADH) and
TPNH (NADPH). Unfortunately, many articles authored by Lars Ernster
and colleagues are not indexed in PUBMED, however, those published
in Acta Chemica Scandinavica since 1947 are available in this link
http://actachemscand.org. Almost simultaneously, the enzyme has
been identified by Märki and Martius (Maerki and Martius, 1961)
which they termed vitamin K reductase (Ernster et al., 1962). Quinone
reductases with properties similar to that described by Ernster have
been reported earlier by Wosilait and colleagues (Wosilait and Nason,
1954), (Wosilait et al., 1954), Williams and colleagues (Williams Jr.
et al., 1959), Giuditta and Strecker (Giuditta and Strecker, 1959),
(Giuditta and Strecker, 1961) and Koli and colleagues (Koli et al.,
1969). From the mechanistic point of view, a DT-diaphorase (EC
1.6.5.2, formerly assigned to EC 1.6.99.2) catalyzes the 2-electron re-
ductive metabolism oxidizing NAD(P)H, thus providing NAD(P)+,
while reducing suitable quinones. Research on diaphorases was intense
until the 60’s as it was believed them to be an important part of energy-
harnessing in mitochondria, but the field became essentially dormant
when Mitchell’s chemiosmotic theory was universally accepted. Several
isoforms have been identified (Long 2nd and Jaiswal, 2000), (Vasiliou
et al., 2006); among them, NQO1 and NQO2 have been most ex-
tensively characterized (Long 2nd and Jaiswal, 2000). A striking dif-
ference among them is that NQO2 uses dihydronicotinamide riboside
(NRH), while NQO1 uses NAD(P)H as an electron donor (Wu et al.,
1997), (Zhao et al., 1997). NQO1 is distributed in the cytosol and mi-
tochondria (Ernster et al., 1962), (Dong et al., 2013), (Bianchet et al.,
2004), (Eliasson et al., 1999), (Edlund et al., 1982), (Conover and
Ernster, 1962), (Conover and Ernster, 1960), (Wosilait, 1960), (Colpa-
Boonstra and Slater, 1958), (Lind and Hojeberg, 1981), but see (Winski
et al., 2002). Total mitochondrial diaphorase activity corresponds to
3–15% of total cellular activity (Ernster et al., 1962), (Edlund et al.,
1982), (Wosilait, 1960), (Colpa-Boonstra and Slater, 1958), (Lind and
Hojeberg, 1981) and is localized in the matrix, since it reacts only with
intramitochondrial reduced pyridine nucleotides, but is inaccessible to
those added from the outside (Conover and Ernster, 1960), (Conover
and Ernster, 1963). Several other mitochondrial enzymes may exhibit
diaphorase-like activity, such as the DLD subunit of KGDHC (Massey,
1960), (Klyachko et al., 2005), (Reed and Oliver, 1968), (Ide et al.,
1967), (Bando and Aki, 1992), (Vaubel et al., 2011).
In 2014 we reported that mitochondrial diaphorases in the mouse
liver contribute up to 81% to the NAD+ pool during respiratory in-
hibition (Kiss et al., 2014). This was sufficient to maintain operation of
KGDHC, which is essential for provision of succinyl-CoA to succinyl-
CoA ligase manifesting in the forward operation of adenine nucleotide
translocase, thus supporting mSLP, see Fig. 2. No such phenomena were
observed in mitochondria obtained from pigeon liver, where DT-dia-
phorases are known to be absent (Kiss et al., 2014), and references
therein. Relevant to this, it is noteworthy that 1–4% of the human
population exhibit a polymorphic version of NQO1; tissues from these
individuals do not exhibit NAD(P)H: quinone oxidoreductase activity
(Traver et al., 1997). Furthermore, we also showed that quinone re-
oxidation (for the diaphorases) was mediated by complex III; this is in
line with the first reports by Conover and Ernster noting that electrons
provided by diaphorase substrates enter the electron transport chain at
the level of cytochrome b of complex III (Conover and Ernster, 1962). In
accordance to this, by studying cyanide-resistant respiration and using
artificial acceptors in isolated mitochondria, the group of Iaguzhinskii
reported the stimulatory effect of various diaphorase substrates
(Kolesova et al., 1991), (Kolesova et al., 1993), (Kolesova et al., 1987),
(Kolesova et al., 1989). Consistent with this, menadione conferred
protection in an ischemia model, and this was abolished by the complex
III inhibitor myxothiazol (Yue et al., 2001), in agreement with the
finding that menadione supports mitochondrial respiration with an
inhibited complex I but not complex III (Conover and Ernster, 1962).
Also, the cytotoxicity caused by complex I inhibitor rotenone, but not
that caused by complex III inhibitor antimycin, was prevented by CoQ1
or menadione (Chan et al., 2002). Similarly, in HepG2 cells, lympho-
cytes and primary hepatocytes, both idebenone and CoQ1, but not
CoQ10, partially restored cellular ATP levels under conditions of im-
paired complex I function, in an antimycin-sensitive manner (Haefeli
et al., 2011), (Chan et al., 2002), (Dedukhova et al., 1986). More re-
cently, in 2018 we reported that 2-methoxy-1,4-naphtoquinone (MNQ)
is preferentially reduced by matrix Nqo1 yielding NAD+ to KGDHC
(Ravasz et al., 2018). Collectively, our results implied that the re-oxi-
dization of substrates being used by the diaphorases for generation of
NAD+ during respiratory arrest by rotenone is mediated by complex III.
This protective mechanism by matrix diaphorases comes into play when
ETC is inhibited by complex I inhibitors and not in the presence of
anoxia, because in the latter case electron acceptors for complex III are
not available. However, p66Shc, a protein residing in the inter-
membrane space of mitochondria (Ventura et al., 2004), (Giorgio et al.,
2005), is known to oxidize cytochrome c (Giorgio et al., 2005) and it
could be possible that oxygen unavailability may not hinder the pro-
tective function of diaphorases. Even oxidized glutathione has been
reported to reduce cytochrome c (Ames and Elvehjem, 1946), (Painter
and Hunter Jr., 1970). Reduction of cytochrome c in vitro by mi-
tochondrial thioredoxin reductase (TrxR2) using NADH has also been
reported (Nalvarte et al., 2004). Ascorbate is also a potentially suitable
oxidizing agent that can re-oxidize cytochrome c, and it is well-known
that neurons may harbor large amounts of ascorbate (Grunewald,
1993). Overall, provision of suitable quinones to matrix diaphorases
may ensure adequate NAD+ for KGDHC, when the electron transport
chain is inhibited. A considerable amount of published data exists
linking diaphorases to neurodegenerative diseases, but they are eval-
uated exclusively from the point of view that diaphorases act upon
redox-active substances, thus it will not be reviewed.
5. Acute provision of NAD+ through reversal of mitochondrial
malate dehydrogenase
Mitochondria harbor an NAD+-dependent malate dehydrogenase
encoded by MDH2 catalyzing the reaction: malate + NAD+< ->ox-
aloacetate + NADH. MDH2 is strongly favored towards reduction of
oxaloacetate due to a large positive change of ΔG (+28.04 kJ/mol
(Chinopoulos, 2013). However, in mitochondria, it proceeds towards
oxaloacetate because the larger ΔG in the negative range (-36.6 kj/mol
(Chinopoulos, 2013) of citrate synthase pulls the reaction along and
keeps oxaloacetate concentration at a very low level. MDH2 is also
subject to regulation by several metabolites: the enzyme is activated by
citrate in the NAD+ ->NADH direction and inhibited by citrate in the
NADH ->NAD+ direction (Mullinax et al., 1982), (Havrankova et al.,
1979). Regulation of MDH2 by citrate maybe of physiological sig-
nificance (McEvily et al., 1985), as the citrate dissociation constant is
~2 mM, thus within the physiological range concentration (Siess et al.,
1977), (Tischler et al., 1977), (Watkins et al., 1977). The potential
physiological role of MDH2 regulation is further supported by the
finding that citrate synthase and MDH2 form a complex (Fahien and
Kmiotek, 1983) while oxaloacetate controls citrate synthase activity
(Krebs, 1970). Oxaloacetate also controls MDH2 activity (Raval and
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Wolfe, 1963), (DuVal et al., 1985). Furthermore, MDH2 is inhibited by
ATP, ADP, AMP, fumarate, and aspartate, (Casado et al., 1980), (Oza
and Shore, 1973), it is affected by ionic strength (Kun et al., 1967)
(though changes in ionic strength may not occur within the mi-
tochondrial matrix), while its activity is enhanced by lysine acetylation
(Zhao et al., 2010). Kinetic modeling of MDH2 activity has been re-
ported by the group of Beard (Dasika et al., 2015).
From the above, one may deduce that it may well be possible that
MDH2 can be regulated to operate towards NADH oxidation, see Fig. 2;
indeed, this is exactly what has been inferred by Hunter in 1949
(Hunter Jr., 1949): he showed that in kidney and liver tissue of the rat
during anoxia, α-ketoglutarate is oxidized to succinate and CO2, while
oxaloacetate is reduced to malate. This practically means that α-ke-
toglutarate was being transformed to succinyl-CoA using NAD+ coming
from mitochondrial malate dehydrogenase reversal. It is not necessary
to have MDH2 reversal in full: in the human brain –as well as other
tissues- MDH2 activity is much higher than that of the remaining en-
zymes of the citric acid cycle (Bubber et al., 2005), see Fig. 3; more
specifically, MDH2 exhibits a ~40 times higher activity compared to
that of KGDHC. Thus, even a mild activity of MDH2 operating in reverse
may suffice for yielding NAD+ for KGDHC. The availability of cells
from patients suffering from MDH2 deficiency (Ait-El-Mkadem et al.,
2017), as well as the recently described specific MDH2 inhibitors (Ban
et al., 2016), (Lee et al., 2013), (Naik et al., 2014) may provide valuable
tools in deciphering the potential contribution of MDH2 reversal pro-
viding NAD+ in the matrix of anoxic mitochondria. Finally, it may be of
value to consider that MDH2 activity is elevated in brains of patients
that died with Alzheimer’s disease (Bubber et al., 2005), (Op den Velde
and Stam, 1976), (Shi and Gibson, 2011), perhaps serving the purpose
of alleviating a decrease in matrix [NAD+]. One potential issue arising
though from the assertion that reverse MDH2 flux could be a source of
NAD+ is that this would lead to a build-up in fumarate concentration in
the matrix, especially in view of the fact that SDH directionality also
remains towards production of fumarate. Several mechanisms are in
place that could compensate this build-up: i) both succinate and fu-
marate may exit mitochondria and this is indeed what sustains the
“hypoxic response” mediated through HIF-1α (Benit et al., 2014),
(Raimundo et al., 2011), (Semenza, 2007), (Guillemin and Krasnow,
1997); ii) in humans, fumarate is a substrate for three reactions, dihy-
droorotate dehydrogenase, (EC 1.3.98.1), fumarate hydratase (EC
4.2.1.2) and argininosuccinate lyase (EC 4.3.2.1); iii) fumarate is also a
product in four other reactions some of which could operate in reverse
diminishing fumarate concentration, namely fumarylacetoacetase (EC
3.7.1.2), acylpyruvate hydrolase (EC 3.7.1.5), oxaloacetate decarbox-
ylase (EC 4.1.1.112) and adenylosuccinate lyase (EC 4.3.2.2). Reverse
SDH operation diminishing fumarate concentration does not occur to an
appreciable extent, for the reasons outlined in (Chinopoulos, 2019).
Thus, a potential fumarate build-up due to reverse MDH2 operation in
concert with fumarate hydratase reaction can be alleviated via multiple
ways.
6. Acute provision of NAD+ through reversal of isocitrate
dehydrogenase
There are 3 isoforms of isocitrate dehydrogenase: A cytosolic
NADP+-dependent (IDH1), a mitochondrial NADP+-dependent (IDH2),
and a mitochondrial NAD+-dependent (IDH3). Under acidic conditions,
IDH2 has been documented to operate in reverse towards formation of
NADP+, reductively carboxylating α-ketoglutarate to isocitrate (Wise
et al., 2011), (Nadtochiy et al., 2016). Relevant to this, it is important to
emphasize that acidic pH is a hallmark of ischemia/hypoxia (Rouslin
and Broge, 1989), (Katsura et al., 1991). It can be envisaged that in
concert with NAD(P) transhydrogenase encoded by NNT gene, a re-
verse-operating IDH2 could generate NAD+. However, succinate gen-
eration in ischemia in a setting that depends on matrix NAD+ provision
(see under “acute provision of NAD+ through residual complex I ac-
tivity” in tissues obtained from either C57BL6N or C57BL6J mice were
similar; this is surprising, because the C57BL/6J mouse strain (from Jax
labs) exhibits a polymorphism in the Nnt gene, while the C57BL/6N
mouse (from EV Taconic) does not have this mutation. Thus, NNT may
not have a role in NAD+ formation through IDH2 reversal (Brookes PS,
personal communication). The sole role of NNT has been addressed in
Fig. 2. Reactions oxidizing NADH in the matrix
during mitochondrial respiratory arrest. α-Kg: α-ke-
toglutarate; c I: complex I of the respiratory chain; c
III: complex III of the respiratory chain; c IV: com-
plex IV of the respiratory chain; FH: fumarate hy-
dratase; GLUD: glutamate dehydrogenase; GOT1:
aspartate aminotransferase isoform 1 (cytosolic)
GOT2: aspartate aminotransferase isoform 2 (mi-
tochondrial); KGDHC: α-ketoglutarate dehy-
drogenase complex; MDH1: malate dehydrogenase
isoform 1 (cytosolic); MDH2: malate dehydrogenase
isoform 2 (mitochondrial); SDH: succinate dehy-
drogenase; SUCL: succinate-CoA ligase; UQ:
Ubiquinone; UQH2: Ubiquinol. The entity trans-
porting NAD+ across the inner mitochondrial mem-
brane remains to be identified.
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(Kiss et al., 2014) and no evidence as matrix NAD+ donor was found at
least in these settings (inhibited respiratory chain, isolated mouse liver
mitochondria), while NNT is known to play an immense role regarding
NAD(P)+ provision in other experimental models, reviewed in (Xiao
and Loscalzo, 2019). Regarding the mitochondrial NAD+-dependent
IDH3, the possibility of this enzyme operating in reverse potentially
providing NAD+ has never been thoroughly examined and at this stage
it cannot be excluded. Activity of KGDHC (oxidative decarboxylation of
α-ketoglutarate) and reverse operation of IDH3 and perhaps IDH2
(reductive carboxylation of α-ketoglutarate) may occur simultaneously
without depleting the matrix from α-ketoglutarate; this is because the
latter metabolite originates from either glutamate dehydrogenase and/
or aspartate aminotransferase, two enzymes with much higher specific
activities than both KGDHC and IDH2/3 (Plaitakis and Zaganas, 2001),
(McKenna, 2011). This is also why it is meaningful that glutamate de-
hydrogenase is subject to complex allosteric regulation by several me-
tabolites, controlling the flux of glutamate oxidation in the citric acid
cycle (Plaitakis and Zaganas, 2001).
7. Acute provision of NAD+ through residual complex I activity
Complex I is instrumental in maintaining NADH oxidation and
ubiquinone reduction allowing oxidative phosphorylation, provided
that oxygen is available and no other impediments within the re-
spiratory chain are present; however, it must be emphasized that its
deficiency does not lead to a lethal phenotype: this is best exemplified
by the fact that complex I-associated pathology spans a variety of dis-
orders, i.e. it is not immediately incompatible with life (Abramov and
Angelova, 2019). However, when this complex is intact but its opera-
tion is hindered by downstream blockade of the respiratory chain as it
occurs in hypoxia, residual activity may play a critical role in main-
taining sufficient NADH oxidation for supporting KGDHC with NAD+ in
the citric acid cycle. Indeed, in 1967, Hoberman and Prosky reported
that inclusion of rotenone in the Ringer’s liver perfusate with a limited
O2 tension mimicking incomplete anaerobiosis yielded less succinate
than in the absence of this complex I inhibitor (Hoberman and Prosky,
1967). In the same line of thought, the group of Brookes showed that
during anoxia, rotenone also led to a decrease in succinate production
in primary cardiomyocytes (Zhang et al., 2018). Mindful that in anoxia,
succinate originates mostly from the canonical activity of the citric acid
cycle and not through reversal of succinate dehydrogenase (Zhang
et al., 2018), (Chinopoulos, 2019), it may well be possible that complex
I exhibits sufficient residual activity for oxidizing NADH yielding NAD+
that can support KGDHC activity and ultimately succinate production
though mSLP. This is not far-fetched, considering the model published
by Jin and Bethke (Jin and Bethke, 2002): The rate equation for com-
plex I activity (J_C1) can be formulated as:
J_C1 = Vmax * [NADH]/[NAD+]total pool * [Q]/[Q]total pool *
FT, where FT is thermodynamic drive. All concentrations are in matrix,
[NAD]total pool = [NAD+] + [NADH]; [Q]total pool = [Q] + [QH2].
Acknowledging that in the reaction catalyzed by complex I one
molecule of NADH is oxidized to NAD+, one molecule of Q is reduced
to QH2 and 4 protons are pumped out of the matrix, complex I activity
can be expressed as a function of QH2/Q and NAD+/NADH. The redox
ratio of CoQ9 and CoQ10 (QH2/Q) varies from 0.1 to 100 (Turunen
et al., 2004), (Galinier et al., 2004), in plasma ~20 (Yamamoto and
Yamashita, 1997), and in submitochondrial particles 0.1–5 (Kroger and
Klingenberg, 1973), while matrix NAD+/NADH fluctuates between 0.1
and 10 (Kulkarni and Brookes, 2019). As shown in Fig. 4, the blue area
of the 3D plot represents complex I activity (expressed in nmol*e-/min/
mg) during a wide range of QH2/Q and NAD+/NADH values. In the red
area, complex I activity is outlined during anoxic conditions, i.e. when
QH2/Q is expected to be very high, and NAD+/NADH very low. It is
immediately evident that even under these conditions complex I may
retain 9–25% of its total activity to oxidize NADH. From this mathe-
matical modeling it can be inferred that complex I does retain a residual
Fig. 3. Activities of tricarboxylic acid cycle in brains from humans and mice. Note the differences in the vertical axis. The values for humans are the means± SEM of
13 brains. The values for mice are the means of± SEM of four mice. PDHC = pyruvate dehydrogenase complex; ICDH = isocitrate dehydrogenase; KGDHC = α-
ketoglutarate dehydrogenase complex; STH = succinate thiokinase; SDH = succinate dehydrogenase; CS = citrate synthase; MDH = malate dehydrogenase.
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activity even during anoxic conditions, thus exhibiting the capacity for
NADH oxidation to the extent of yielding NAD+ for KGDHC.
Having said that, it is important to emphasize that the decrease in
NAD+/NADH observed by NADH autofluorescence (Scholz et al., 1995)
during anoxia may be overestimated. This is because the binding of
NADH to complex I enhances its fluorescence (Blinova et al., 2008)
leading to the erroneous impression of an increase in [NADH]. Recent
technological advances (Blacker et al., 2014), may provide more ac-
curate measurements regarding matrix NAD+/NADH of mitochondria
with a dysfunctional respiratory chain (Blacker and Duchen, 2016).
8. Acute provision of NAD+ through reverse-operating malate-
aspartate shuttle
Apart from residual activity of complex I and the aforementioned
mechanisms, other sources of NADH oxidation may be present: indeed
it was shown that inhibition of complex I (but not complex III) allowed
fatty acid oxidation to continue, a process which is dependent on pro-
vision of NAD+ (and FAD) (Chen et al., 2016). Such a mechanism may
be substantiated by a reducing equivalent shuttle. NADH generated in
the cytosol through glycolysis must be converted back to NAD+ for the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) reaction to sus-
tain glycolytic flux. Under normoxic conditions this is carried out by the
malate-aspartate shuttle (MAS), see Fig. 2. The shuttle consists of a
cytosolic isoform of MDH converting oxaloacetate to malate using
NADH. Malate is then transported into the mitochondrial matrix where
MDH2 converts it back to oxaloacetate yielding NADH. In turn, ox-
aloacetate is converted to aspartate with the addition of an amino group
from glutamate by aspartate aminotransferase (GOT2) also yielding α-
ketoglutarate. This α-KG is then transported out of mitochondria in
exchange for malate. Expulsion of aspartate and import of glutamate is
mediated by the mitochondrial glutamate-aspartate carrier. The cyto-
solic GOT1 then catalyzes the reverse reaction (aspartate + α-ke-
toglutarate → oxaloacetate + glutamate). All in all, the reducing power
of cytosolic NADH is transferred into the matrix without the direct
transport of the pyridine nucleotide. The concept of this shuttle has
been suggested by Borst in 1963 (Borst, 1963); it can even be recon-
stituted in vitro and mediate the oxidation of added NADH in isolated
mitochondria (Lumeng and Davis, 1970), (LaNoue and Williamson,
1971). Even though the MAS has been considered to be unidirectional
under normal conditions, the possibility of operating in reverse during
de-energized conditions has been suggested in 1975 by Bremer and
Davis in (Bremer and Davis, 1975). More recently, the same concept has
been put forward by the group of Murphy (Chouchani et al., 2014).
From the thermodynamic point of view, the reversal potential of
MAS (Erev_MAS, the mitochondrial membrane potential at which the
















where R = 8.314 J/(mol K), T = 310 K (37°C) and F = 96485 C/mol;
“m” signifies matrix, and “c” cytosol. Furthermore, mindful of the
participation of the glutamate-aspartate carrier in MAS which co-
transports protons and assuming that the process is:
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From the above equations it is evident that MAS directionality is
governed by cytosolic [NAD+], [NADH], mitochondrial [NAD+],
[NADH], ΔpH, cytosolic [glutamate] and [aspartate] and mitochondrial
[glutamate] and [aspartate]. It would be too complicated to graphically
represent MAS as a function of all these parameters, but it can be de-
duced that MAS may tend to operate in reverse (removing reducing
power of NADH from the matrix) when i) mitochondria are de-en-
ergized (low ΔΨm) ii) matrix NAD+/NADH is low, and iii) cytosolic
NAD+/NADH is high. These considerations lend support to the sug-
gestion that MAS may indeed operate in reverse during de-energized
(i.e. anoxic) conditions, as suggested in (Bremer and Davis, 1975) and
(Chouchani et al., 2014). Finally, it may be of value to acknowledge
that in the cytosol NAD+ may not only originate from MDH1 or lactate
dehydrogenase, but also from the process of desaturating fatty acids
(Kim et al., 2019), alcohol dehydrogenases and aldehyde dehy-
drogenases (Cederbaum, 2012), increasing the likelihood for MAS re-
versibility.
9. Acute provision of NAD+ through NAD+ import across the
inner mitochondrial membrane
The concept of MAS has been put forward exactly because NAD+
was considered impermeable to the inner mitochondrial membrane
(Chappell, 1968), (Stein and Imai, 2012), whereas cytosolic and nuclear
NAD+ pools are exchangeable via diffusion through connexin 43 and
the nuclear pore, respectively (Bruzzone et al., 2001), (Verdin, 2015).
However, in 1997 Rustin and colleagues reported that NAD+ is able to
cross the inner mitochondrial membrane (Rustin et al., 1997). This has
been more recently confirmed by the group of Baur using isotope la-
belling experiments (Davila et al., 2018), even though to date, no me-
chanism for direct NAD+ transport in mammalian mitochondria has
been identified. Although the results are unequivocal, it begs the
question why are there shuttles, if NAD+ can be directly imported;
perhaps the rate of reducing equivalents appearing in the matrix of one
mechanism over another is very different. Furthermore, this mechanism
seems to be unidirectional, because mitochondria expressing a bacterial
enzyme mediating strong NADH oxidation (mitoLbNOX, see under
“artificial means of manipulating matrix NAD+/NADH”) drained re-
ducing equivalents from the whole cell, while LbNOX expressed in the
cytosol only oxidized the cytosol (Titov et al., 2016). By the same token,
since mitoLbNOX, but not LbNOX, increased the mitochondrial NAD+/
Fig. 4. Mathematical modeling of complex I activity expressed in nmol*e-/min/
mg as a function of QH2/Q and NAD+/NADH. Blue area represents activity
over a very wide range of QH2/Q and NAD+/NADH values. Red area represents
activity during anoxia, when QH2/Q is expected to be very high, and NAD+/
NADH very low. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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NADH ratio in HeLa cells, this means that import of NAD+ to mi-
tochondria may not be quantitatively important, at least in this setting.
It would have been of interest to perform experiments in LbNOX and
mitoLbNOX-expressing cells when mitochondria are de-energized, and
examine the extent of contribution of MAS reversibility in contributing
the transfer of reducing power of pyridine nucleotides from the cytosol.
10. Artificial means of manipulating matrix NAD+/NADH
In 2016, the group of Mootha published the results of expressing a
water-forming NADH oxidase from Lactobacillus brevis (LbNOX) as a
genetic tool for inducing a compartment-specific increase of the NAD
(+)/NADH ratio in human cells, which they also targeted to mi-
tochondria (mitoLbNOX) (Titov et al., 2016). With this, they clearly
demonstrated the compartment-specific manipulation of NAD+/NADH
ratio and its impact on redox-dependent events. By using this tool, it
would be easy to address the role of [NAD+] in metabolic settings di-
rectly, as opposed to manipulating electron transport chain which in-
directly affects matrix NAD+/NADH. Even more recently, the same
group reported the engineering of a fusion of bacterial lactate oxidase
(LOX) and catalase (CAT) named LOXCAT (Patgiri et al., 2020). This
fusion enzyme exhibits the capacity of irreversibly converting lactate
and oxygen to pyruvate and water and as an extension to that impact on
intracellular NAD+/NADH ratio. By injecting purified LOXCAT in
living mice, beneficial changes in intracellular NAD+/NADH ratio were
observed in response to a metformin-induced rise in blood lactate/
pyruvate ratio.
Also, the use of β-hydroxybutyrate vs acetoacetate in regulating
matrix NAD+/NADH ratio is a well-known and widely employed tool,
through the reaction catalyzed by β-hydroxybutyrate dehydrogenase,
see Fig. 2. Of course, this is only applicable for mitochondria expressing
this enzyme, and in most circumstances the amount of β-hydro-
xybutyrate and/or acetoacetate used needs to be titrated (Chinopoulos
et al., 2010), (Kiss et al., 2013), (Kiss et al., 2014), (Ravasz et al., 2018).
The possibility of NAD+ originating from reverse activity of gluta-
mate dehydrogenase, to the best of my knowledge, has never been re-
ported; however, the substrate combination of α-ketoglutarate + ma-
late was eliciting stronger mSLP than either glutamate + malate or α-
ketoglutarate + glutamate + malate in isolated mitochondria, im-
plying that NADH production by glutamate dehydrogenase from glu-
tamate to α-ketoglutarate diminishes the availability of NAD+ for
KGDHC (Chinopoulos et al., 2010), (Kiss et al., 2013), (Kiss et al.,
2014), (Ravasz et al., 2018).
11. Conclusions
Hereby several acute sources of NADH oxidation are discussed; it
must be born in mind that each of them may attain a condition-de-
pendent role, and that some may be trivial. Furthermore, the present
review addresses only the acute sources of NAD+ in the mitochondrial
matrix; having said that, contribution of NAD+ from production path-
ways as reviewed by (Kulkarni and Brookes, 2019) and (Katsyuba et al.,
2020) must not be ignored, but they can be considered as subacute and/
or chronic means for yielding NAD+ simply because they are governed
by slower kinetics.
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